GlassScriptPhysician profile
Katherine D Matta
NPI 1114129053
$2,116.30
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $408 · 2021: $502 · 2022: $273 · 2023: $163 · 2024: $69.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $546.41 | 2019-2023 | |
| Therapeuticsmd, INC. | $290.94 | 2019-2022 | |
| Evofem Biosciences, INC. | $262.72 | 2021-2022 | |
| Lupin INC. | $253.49 | 2019-2020 | |
| Pfizer INC. | $193.52 | 2019-2023 | |
| Coopersurgical, INC. | $166.09 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Avion Pharmaceuticals | $147.79 | 2019-2021 | |
| Allergan, INC. | $77.62 | 2019-2020 | |
| Medicem INC. | $59.45 | 2020-2022 | |
| Millicent US INC | $33.07 | 2019 | |
| Dentsply Sirona INC | $19.28 | 2019 | |
| Hologic Sales and Service, LLC | $18.33 | 2024 | Thinprep 2000 Processor, Aptima |
| Agile Therapeutics, INC. | $17.98 | 2023 | Twirla |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Matta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.